Target intelligence / Profile preview

Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha (Nav1.1, Nav1.2, Nav1.3)

Target
Nav1.1, Nav1.2, Nav1.3
Molecular classification
Ion channel, Voltage-gated ion channel
01

Overview

Voltage-gated sodium channels (VGSCs) of the Nav1.1, Nav1.2, and Nav1.3 subtypes are critical transmembrane proteins that conduct sodium ions across neuronal membranes in response to changes in membrane potential[1][3][7][9]. Each channel is formed by a large α-subunit (encoded by SCN1A, SCN2A, or SCN3A) with four homologous domains (DI–DIV), each comprising six transmembrane segments. The S4 segment in each domain acts as a voltage sensor; upon depolarization, the channel opens, allowing sodium influx and initiating the action potential. Rapid inactivation is mediated by an intracellular loop, crucial for repolarization and repetitive firing control[3][9]. These subtypes are primarily expressed in the central nervous system, with distinct but overlapping distribution patterns. Mutations in their genes are strongly linked to epilepsy, neurodevelopmental disorders, and other neurological syndromes[8]. Voltage-gated sodium channels are established therapeutic targets for anticonvulsants, local anesthetics, and antiarrhythmic drugs, but their high sequence homology poses challenges for isoform-selective drug development[2][4][7].

Other names
Nav1.1 (SCN1A)Nav1.2 (SCN2A)Nav1.3 (SCN3A)voltage-gated sodium channel alpha subunit (types I, II, III)VGSC
02

Mechanism of action

Blockade (inhibition) of sodium influx to prevent action potential firing Use-dependent blockade (preferential inhibition of overactive neurons) Modulation of channel inactivation states

03

Biological functions

Generation and propagation of action potentialsSignal transduction in excitable cellsRegulation of neuronal excitability
04

Disease associations

EpilepsyNeurodevelopmental disordersNeuropathic painOther neurological diseases
05

Safety considerations

Cardiac arrhythmias due to off-target effectsCNS side effects (e.g., sedation, ataxia)Poor subtype selectivity leads to narrow therapeutic indexRisk of worsening or provoking seizures in some channelopathies
06

Interacting drugs

Phenytoin

8 more in the full profile.

07

Biomarkers

Mutations in SCN1A, SCN2A, or SCN3A genes for genetic epilepsy diagnosisExpression profiles in neurological tissues for disease states

Beyond the preview

Go deeper on Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha (Nav1.1, Nav1.2, Nav1.3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium channel protein type 1 subunit alpha, Sodium channel protein type 2 subunit alpha, Sodium channel protein type 3 subunit alpha (Nav1.1, Nav1.2, Nav1.3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call